Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma

被引：44
作者：
Hao, H. [1 ]
Chen, L. [1 ]
Huang, D. [1 ]
Ge, J. [1 ]
Qiu, Y. [1 ]
Hao, L. [1 ]
机构：
[1] Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Jiangxi Prov Key Lab Mol Med, Nanchang, Jiangxi, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER CARE | 2017年 / 26卷 / 05期
关键词：
alkaline phosphatase; osteosarcoma; prognosis; PRIMARY OSTEOGENIC-SARCOMA; NEOADJUVANT CHEMOTHERAPY; EXPERIENCE; BONE; METASTASIS; EXTREMITY; ADJUVANT; RIZZOLI; BIAS;
D O I：
10.1111/ecc.12536
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Many studies have evaluated the relationships between alkaline phosphatase (ALP) levels and the prognosis for osteosarcoma. However, a consensus has yet to be reached. We completed a meta-analysis to assess the significance of ALP and prognosis for osteosarcoma. We retrieved eligible documents from the PubMed and Embase databases and extracted related data from those documents. The overall survival (OS), hazard ratio (HR) and event-free survival (EFS) HR were obtained after combination to evaluate the impacts of ALP levels on prognosis for osteosarcoma. After screening, a total of 12 documents published between 1999 and 2013 were included. The ALP levels on OS were evaluated in nine documents. The pooled HRs was 1.78 (95% CI: 1.52-2.07, p<.05). The ALP levels on EFS were determined in eight documents. The pooled HRs was 1.58 (95% CI: 1.37-1.82, p<.05). Begg's test (OS, p>.754; EFS, p>.386) and Egger's test (OS, p>.649; EFS, p>.274) showed that there was no significant publication bias during analytic process. In summary, our meta-analysis shows that a higher level of ALP can decrease the OS and EFS in patients with osteosarcoma and ALP is an important biological indicator for patients with osteosarcoma.
引用
收藏
页数：7
相关论文
共 37 条
[1]  
[Anonymous], EUROPEAN J CANC CARE
[2]   Long-term results after combined modality treatment for non-metastatic osteosarcoma [J].
Aparicio, J ;
Segura, A ;
Montalar, J ;
Garcerá, S ;
Oltra, A ;
Santaballa, A ;
Yuste, A ;
Pastor, M ;
Munárriz, B .
MEDICAL ONCOLOGY, 1999, 16 (04) :255-260
[3]  
Arai Yasuhiro, 2007, Nihon Kokyuki Gakkai Zasshi, V45, P962
[4]   Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy [J].
Bacci, G ;
Longhi, A ;
Fagioli, F ;
Briccoli, A ;
Versari, M ;
Picci, P .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (18) :2836-2845
[5]   Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: Experience at rizzoli on 1421 patients treated over the last 30 years [J].
Bacci, G ;
Longhi, A ;
Ferrari, S ;
Briccoll, A ;
Donati, D ;
De Paolis, M ;
Versari, M .
TUMORI, 2004, 90 (05) :478-484
[6]   PUBLICATION BIAS - A PROBLEM IN INTERPRETING MEDICAL DATA [J].
BEGG, CB ;
BERLIN, JA .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 1988, 151 :419-463
[7]   Addition of Muramyl Tripeptide to Chemotherapy for Patients With Newly Diagnosed Metastatic Osteosarcoma [J].
Chou, Alexander J. ;
Kleinerman, Eugenie S. ;
Krailo, Mark D. ;
Chen, Zhengjia ;
Betcher, Donna L. ;
Healey, John H. ;
Conrad, Ernest U., III ;
Nieder, Michael L. ;
Weiner, Michael A. ;
Wells, Robert J. ;
Womer, Richard B. ;
Meyers, Paul A. .
CANCER, 2009, 115 (22) :5339-5348
[8]   THE COMBINATION OF ESTIMATES FROM DIFFERENT EXPERIMENTS [J].
COCHRAN, WG .
BIOMETRICS, 1954, 10 (01) :101-129
[9]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[10]   Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients [J].
Durnali, Ayse ;
Alkis, Necati ;
Cangur, Sengul ;
Yukruk, Fisun Ardic ;
Inal, Ali ;
Tokluoglu, Saadet ;
Seker, Mehmet Metin ;
Bal, Oznur ;
Akman, Tulay ;
Inanc, Mevlude ;
Isikdogan, Abdurrahman ;
Demirci, Ayse ;
Helvaci, Kaan ;
Oksuzoglu, Berna .
MEDICAL ONCOLOGY, 2013, 30 (03)
1234